Extension Study in Japanese PV and ET Patients

Phase 3

Recruiting

• Conditions: Polycuthemia Vera and Essential Thrombocythemia; Myeloproliferative nemoplasms

• Registration Number: JPRN-jRCT2031200269
• Lead Sponsor: Kawase Hiroaki

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-24
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 67

Inclusion Criteria

1. Patients who have completed the 52-week P1101 treatment duration in Study A19-201 and are considered by the investigator or subinvestigator to be eligible for participation in this study
2. Patients who have completed the follow-up/end-of-study visit in Study P1101 ET and are considered by the investigator or subinvestigator to be eligible for participation in this study
3. Patients who have given written informed consent to participate in this study

Exclusion Criteria

1. Patients who are considered by the investigator or subinvestigator to be ineligible for continued treatment with P1101 or switch from anagrelide to P1101

Study & Design

• Study Type: Interventional
• Study Design: Not specified